Effect Of Rifampin On Pharmacokinetics Of Sitaxsentan

A Phase 1, Open Label, Fixed Sequence Design, Multiple Dose Study To Assess The Effect Of Rifampin On The Pharmacokinetics Of Sitaxsentan In Healthy Subjects

This study will assess how rifampin will affect the blood levels of sitaxsentan. Safety of sitaxsentan given alone and with rifampin will also be assessed.

Inclusion Criteria:

• Healthy male subjects and/or women of non-child bearing potential.
• Subjects between the ages of 21 and 55 years, inclusive.
• Signed informed consent.

Exclusion Criteria:

• Evidence or history of clinically significant hematological, renal, endocrine, pulmonary, gastrointestinal, cardiovascular, hepatic, psychiatric, neurologic, or allergic disease.
• Has hepatic dysfunction.
• Has history of excessive alcohol and tobacco use.